Ann: Investor Presentation, page-30

yes as the FDA decision was made available on Saturday March 11. The market hasn’t woken up to this yet - waiting for Acadia to take the lead in the US overnight then I expect a siginificant uptick again tomorrow. Market didn’t know what to do. We are all waiting on the drug costing to plug into models - expected to be around $150000 p.a per patient reimbursed by insurers. May be more may be less. ASX has so few successful biotechs I genuinely think that most analysts just are lost on valuations for these. Botanix has suffered from this previously - dropping in value after a successful phase 2 study. The mind boggles.